Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma

2.1 Polatuzumab vedotin (Polivy, Roche) in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone is indicated for 'the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL)'.

2.2 The dosage schedule is available in the summary of product characteristics for polatuzumab vedotin.

2.3 Polatuzumab vedotin costs £2,370 per 30 mg vial or £11,060 per 140 mg vial (excluding VAT, BNF online accessed December 2022).

2.4 The company has a commercial arrangement. This makes polatuzumab vedotin available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.